METABOLON APPOINTS ERIC BUTTON SENIOR VICE PRESIDENT OF DIAGNOSTICS
RESEARCH TRIANGLE PARK, N.C. (December 15, 2011) —Metabolon, Inc., a diagnostics and services company offering the industry’s leading biochemical profiling technology, announced today the appointment of Eric Button as Senior Vice President of Diagnostics. In this position, Mr. Button will have responsibility for all aspects of Metabolon’s diagnostics operations, and will report to the company’s CEO John Ryals.
Mr. Button possesses extensive experience in marketing, strategic and business planning, corporate partnering, licensing, R&D management and acquisitions, among other areas, working in both public and privately held companies.
“Eric brings to Metabolon 20 years of entrepreneurial and leadership skills, as well as experience in all phases of business operations,” said Mr. Ryals. “We look forward to the support he will provide our diagnostics division as we develop and bring to market unique products for cancer and other therapeutic areas, and are excited to have him as part of our team.”
Commenting on his appointment, Mr. Button stated, “Metabolon has the leading biochemical platform and is developing inspiring technology in the diagnostic space. My experience in launching both cancer and diabetes diagnostic tests is well-suited for Metabolon, and I am delighted to have the opportunity to work with the talent this company employs and look forward to what we can accomplish.”
Most recently, Mr. Button has served as President of GlycoMark, Inc., where he successfully oversaw the company’s GlycoMark joint venture with Toyota and Nippon Kayaku to launch a medical test for diabetes. Previously he was President and CEO of Amplistar, Inc., a company dedicated to pursuing new approaches to cancer diagnostics, and Founder, President and CEO of Innovex Diagnostics/NovaDx, a diagnostics company focused on osteoporosis and arthritis. Earlier in his career he served in various marketing capacities at Hybritech, a subsidiary of Eli Lilly, where he led the business group responsible for the PSA prostate cancer test. Since 2001 he has been an Adjunct Professor at the University of North Carolina at Greensboro, and has served as guest lecturer on entrepreneurship and marketing to MBA students at Wake Forest University.
Mr. Button holds an MBA from the University of North Carolina-Greensboro, an MS in molecular genetics from the University of British Columbia-Vancouver and a BA in biology from the University of North Carolina-Greensboro, where he was a member of the Phi Beta Kappa honor society.
Metabolon is a clinical diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com or contact Todd Lynch, CFO at firstname.lastname@example.org or 919-572-1711.